Patents by Inventor Uli Bialucha

Uli Bialucha has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20250122290
    Abstract: The invention relates generally to anti-CD161 antibodies, pharmaceutical compositions comprising such antibodies, and methods of using such antibodies for treating disorders associated with or mediated by CD161, for example, certain cancers.
    Type: Application
    Filed: December 19, 2024
    Publication date: April 17, 2025
    Inventors: Alison TISDALE, Uli BIALUCHA, George PUNKOSDY, Alexandria FUSCO, Frano IRVINE, Emily ROSENTRATER, Elizabeth SCANLON, Michael BATTLES
  • Publication number: 20250101075
    Abstract: The present invention provides, among other things, a masked cytokine comprising an attenuated interleukin 2 (IL-2) polypeptide, a VHH masking moiety, a carrier moiety and anti-PD1 targeting moiety. In some embodiments, the IL-2 polypeptide is engineered to be activatable by a protease at a target site, such as in a tumor microenvironment, by including a proteolytically cleavable linker. The VHH masking moiety blocks, occludes, inhibits (e.g., decreases) or otherwise prevents (e g masks) the activity or binding of the cytokine to its cognate receptor or protein. Upon proteolytic cleavage of the cleavable linker at the target site, the IL-2 polypeptide becomes activated, which renders it capable of binding to its cognate receptor or protein with increased affinity.
    Type: Application
    Filed: August 30, 2024
    Publication date: March 27, 2025
    Inventors: Parker JOHNSON, Ertan ERYILMAZ, Dheeraj TOMAR, Benjamin NICHOLSON, Kurt JENKINS, Carl Uli BIALUCHA
  • Patent number: 12215159
    Abstract: The invention relates generally to anti-CD161 antibodies, pharmaceutical compositions comprising such antibodies, and methods of using such antibodies for treating disorders associated with or mediated by CD161, for example, certain cancers. In addition, the invention also relates to expression vectors and host cells for making these antibodies.
    Type: Grant
    Filed: February 21, 2024
    Date of Patent: February 4, 2025
    Assignee: IMMUNITAS THERAPEUTICS, INC.
    Inventors: Alison Tisdale, Uli Bialucha, George Punkosdy, Alexandria Fusco, Frano Irvine, Emily Rosentrater, Elizabeth Scanlon, Michael Battles
  • Publication number: 20240279346
    Abstract: The invention relates generally to anti-CD161 antibodies, pharmaceutical compositions comprising such antibodies, and methods of using such antibodies for treating disorders associated with or mediated by CD161, for example, certain cancers.
    Type: Application
    Filed: February 21, 2024
    Publication date: August 22, 2024
    Inventors: Alison TISDALE, Uli BIALUCHA, George PUNKOSDY, Alexandria FUSCO, Frano IRVINE, Emily ROSENTRATER, Elizabeth SCANLON, Michael BATTLES
  • Publication number: 20240141007
    Abstract: The present disclosure relates to cleavable carriers and cleavable carrier-linked cytokine prodrugs wherein the cleavable carrier is an engineered Fc domain comprising at least one tumor-associated protease cleavage site. Upon cleavage at the cleavage site of the carrier Fc domain, the cytokine is released from a masking moiety. The platform provides enzymatically induced prodrug activation. The present disclosure further provides pharmaceutical compositions comprising said cleavable carrier-linked cytokine prodrugs, their use as a medication as well as methods of treatment of diseases and administration.
    Type: Application
    Filed: July 14, 2023
    Publication date: May 2, 2024
    Inventors: Ertan Eryilmaz, Carl Uli Bialucha, Parker Johnson, Dheeraj Tomar
  • Publication number: 20230365641
    Abstract: The present invention relates to targeted, masked cytokines, comprising a cytokine or functional fragment thereof, a masking moiety, a targeting moiety and a proteolytically cleavable linker. The targeting moiety comprises an antigen-binding moiety that specifically binds to an antigen expressed on the surface of a target cell The masking moiety masks the cytokine or functional fragment thereof thereby reducing or preventing binding of the cytokine or functional fragment thereof to its cognate receptor, but upon proteolytic cleavage of the cleavable linker at a target site, the cytokine or functional fragment thereof becomes activated, which renders it capable or more capable of binding to its cognate receptor.
    Type: Application
    Filed: February 28, 2023
    Publication date: November 16, 2023
    Inventors: Parker Johnson, Ertan Eryilmaz, Dheeraj Tomar, Benjamin Nicholson, Kurt Jenkins, Carl Uli Bialucha
  • Publication number: 20230128499
    Abstract: The present disclosure provides methods of treating a subject having a proliferative disease or an autoimmune disorder with a combination of (a) a first multispecific binding molecule (MBM) that binds specifically to (i) human CD2 and (ii) a human tumor-associated antigen and/or a human tumor microenvironment antigen, and (b) a second multispecific binding molecule that binds specifically to (i) a component of a human T-cell receptor (TCR) complex or a secondary T-cell signaling molecule and (ii) a human tumor-associated antigen and/or human tumor microenvironment antigen. The disclosure further provides MBMs and combinations of MBMs that can be used in the methods of the disclosure.
    Type: Application
    Filed: March 26, 2021
    Publication date: April 27, 2023
    Applicant: Novartis AG
    Inventors: Carl Uli BIALUCHA, Brian GRANDA
  • Patent number: 10238748
    Abstract: The present invention relates to anti-CDH6 antibodies, antibody fragments, antibody drug conjugates, and their uses for the treatment of cancer.
    Type: Grant
    Filed: August 7, 2015
    Date of Patent: March 26, 2019
    Assignee: Novartis AG
    Inventors: Carl Uli Bialucha, Scott Collins, Clemens Dürr, Tiancen Hu, Mary Jo Janatpour, Matthew John Meyer
  • Patent number: 9982045
    Abstract: The present invention relates to anti-CDH6 antibodies, antibody fragments, antibody drug conjugates, and their uses for the treatment of cancer.
    Type: Grant
    Filed: August 7, 2015
    Date of Patent: May 29, 2018
    Assignee: Novartis AG
    Inventors: Carl Uli Bialucha, Scott Collins, Clemens Dürr, Tiancen Hu, Mary Jo Janatpour, Matthew John Meyer
  • Publication number: 20160046711
    Abstract: The present invention relates to anti-CDH6 antibodies, antibody fragments, antibody drug conjugates, and their uses for the treatment of cancer.
    Type: Application
    Filed: August 7, 2015
    Publication date: February 18, 2016
    Applicant: NOVARTIS AG
    Inventors: Carl Uli BIALUCHA, Scott COLLINS, Clemens DÜRR, Tiancen HU, Mary Jo JANATPOUR, Matthew John MEYER
  • Publication number: 20100297010
    Abstract: The present invention is directed to methods of identifying tumor suppressor genes in vivo, tumor suppressors thus found, methods of treatment taking advantage of the identified tumor suppressors, methods of and kits for diagnosis of cancer using the identified tumor suppressor, and pharmaceutical composition comprising an identified tumor suppressor or modulators thereof.
    Type: Application
    Filed: May 16, 2008
    Publication date: November 25, 2010
    Inventors: Anka Bric, Lars Zender, Cornelius Miething, Uli Bialucha, Scott W. Lowe